Peptron Inc (087010) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Peptron Inc (087010) has a cash flow conversion efficiency ratio of -0.050x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-7.30 Billion ≈ $-4.95 Million USD) by net assets (₩146.33 Billion ≈ $99.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Peptron Inc (087010) net asset quality to measure how much of total assets are equity-financed.
Peptron Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Peptron Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Peptron Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Peptron Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Peptron Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polestar Automotive Holding UK PLC Class A ADS
NASDAQ:PSNY
|
0.058x |
|
Planisware SAS
PA:PLNW
|
0.154x |
|
Guobang Pharma Ltd
SHG:605507
|
0.036x |
|
Advantage Oil & Gas Ltd.
TO:AAV
|
0.048x |
|
Tong Yang Industry Co Ltd
TW:1319
|
0.079x |
|
Hengdian Group Tospo Lighting Co Ltd
SHG:603303
|
0.100x |
|
Cosmo Pharmaceuticals N.V
F:C43
|
0.013x |
|
Zhejiang Jingu Co Ltd
SHE:002488
|
0.004x |
Annual Cash Flow Conversion Efficiency for Peptron Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Peptron Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Peptron Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩151.71 Billion ≈ $102.81 Million |
₩-12.77 Billion ≈ $-8.65 Million |
-0.084x | +72.30% |
| 2023-12-31 | ₩36.13 Billion ≈ $24.48 Million |
₩-10.97 Billion ≈ $-7.44 Million |
-0.304x | -37.64% |
| 2022-12-31 | ₩53.11 Billion ≈ $35.99 Million |
₩-11.72 Billion ≈ $-7.94 Million |
-0.221x | -29.48% |
| 2021-12-31 | ₩62.28 Billion ≈ $42.21 Million |
₩-10.61 Billion ≈ $-7.19 Million |
-0.170x | +2.98% |
| 2020-12-31 | ₩77.13 Billion ≈ $52.27 Million |
₩-13.55 Billion ≈ $-9.18 Million |
-0.176x | +48.60% |
| 2019-12-31 | ₩28.09 Billion ≈ $19.03 Million |
₩-9.60 Billion ≈ $-6.51 Million |
-0.342x | -268.75% |
| 2018-12-31 | ₩45.10 Billion ≈ $30.56 Million |
₩-4.18 Billion ≈ $-2.83 Million |
-0.093x | +19.36% |
| 2017-12-31 | ₩48.95 Billion ≈ $33.17 Million |
₩-5.63 Billion ≈ $-3.81 Million |
-0.115x | -124.03% |
| 2016-12-31 | ₩53.21 Billion ≈ $36.06 Million |
₩-2.73 Billion ≈ $-1.85 Million |
-0.051x | +62.48% |
| 2015-12-31 | ₩17.23 Billion ≈ $11.67 Million |
₩-2.36 Billion ≈ $-1.60 Million |
-0.137x | +65.62% |
| 2014-12-31 | ₩7.18 Billion ≈ $4.87 Million |
₩-2.86 Billion ≈ $-1.94 Million |
-0.398x | -- |
About Peptron Inc
Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more